Lv23
122 积分 2021-02-07 加入
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study
1天前
已完结
Understanding Bladder-Sparing Approach in the Modern Era of Neoadjuvant Therapy
3天前
已完结
Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient
6天前
已完结
Re-evaluating aglatimagene in localised prostate cancer
6天前
已完结
Association of ATM Alterations with Outcomes After (177)Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
10天前
已完结
Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer
10天前
已完结
Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026)
14天前
已完结
Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study
15天前
已完结
Beyond the T-Score: Reconsidering the Timing of Bone-Protective Therapy in Men Receiving Androgen Deprivation Therapy for Hormone-Sensitive Prostate Cancer
16天前
已完结
Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection
18天前
已完结
皖公网安备34019202002308
